ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After Positive Dupixent REMODEL Phase 4 Eosinophilic Esophagitis Results
Sanofi (ENXTPA:SAN) stock is back in focus after the company and Regeneron shared REMODEL Phase 4 data for Dupixent in adults with eosinophilic esophagitis, highlighting clinically meaningful benefits in esophageal function and disease measures.
See our latest analysis for Sanofi.
Even with the positive REMODEL data and recent AI and conference updates, Sanofi’s 30-day share price return is down 8.82% and its 1-year total shareholder return is down 14.92%. This suggests recent momentum has...